MC Sciences is a pre-clinical stage company developing a new mast cell therapy platform with small molecules that target a wide range of diseases in immunology, fibrotic diseases, neuroinflammation, gastroenterology and rare diseases related to excessive mast cell activity and dysregulation of the mast cell function.

MC Sciences preferred objective is the comprehensive collaboration with  pharmaceutical companies and / or life sciences venture capital companies to drive the further development of our new mast therapy platform and to bring it successfully to market and patients.

We look forward to your inquiries and engaging in a dialogue on investment and collaboration opportunities. In 2021, we plan investors conferences / meetings to demonstrate our new mast cell therapy platform.